Saturday 17 October 2026
Export ADAG’s income statement to Excel — free account
Adagene Inc. Sponsored ADR
ADAG Healthcare Biotechnology
Adagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024. Insiders bought in the last twelve months.
2.06
0.34
−14.17%
Follow ADAG
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 7.00 | 0.90 | 1.10 | 1.74 | 1.30 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 31.83 | 9.25 | 2.10 | 4.38 | 3.16 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 198 | 259 | 248 | 174 | 138 | 128 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.04 | 0.04 | 0.10 | 0.00 | 0.06 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 1 | 10 | 9 | 18 | 0 | 8 | ||||
| Gross margin, % | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | (16) | (42) | (71) | (80) | (17) | (33) | (18) | |||||
| EBT margin, % | — | — | — | (3,423.40) | (6,048.98) | (702.45) | (855.65) | (95.27) | (32,404.75) | (233.44) | |||||
| Net income | — | 0 | — | (42) | (42) | (73) | (80) | (19) | (33) | (18) | |||||
| Depreciation | — | — | — | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.04 | 0.05 | 0.25 | 0.21 | 0.41 | 0.00 | 0.16 | ||||
| Earnings | — | — | — | (1.35) | (2.67) | (1.46) | (1.48) | (0.35) | (0.59) | (0.30) | |||||
| Cash flow | — | — | — | (2.35) | (2.24) | (1.08) | (1.12) | (0.65) | (0.66) | (0.33) | |||||
| Capex | — | — | — | (0.08) | (0.07) | (0.06) | (0.02) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (2.43) | (2.31) | (1.15) | (1.14) | (0.65) | (0.66) | (0.33) | |||||
| Book value | — | — | — | (4.69) | (7.00) | 3.91 | 1.92 | 1.61 | 1.12 | 0.75 | |||||
| Shares, m | — | — | — | 12 | 13 | 40 | 43 | 44 | 45 | 47 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | — | — | — | — | — | ||||
| P/S | — | — | — | 0.00 | 0.00 | — | — | — | — | — | |||||
| P/B | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | 0.00 | 0.00 | 0.00 | 0.89 | 0.65 | 0.59 | 1.04 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (29) | (29) | (43) | (49) | (28) | (30) | (16) | ||||
| Capex | — | — | — | (1) | (1) | (3) | (1) | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (29) | (29) | (46) | (49) | (29) | (30) | (16) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 97 | 63 | 156 | 94 | 82 | 50 | 52 | ||||
| Total debt | — | — | — | 2 | 4 | 4 | 17 | 18 | 13 | 2 | |||||
| Net debt | — | — | — | (99) | (71) | (170) | (127) | (92) | (72) | (73) | |||||
| Shareholders’ equity | — | — | — | (57) | (89) | 157 | 83 | 71 | 51 | 35 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (31.50) | (44.85) | (53.48) | (46.78) | (14.13) | (32.61) | (21.02) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 22.78 | 58.26 | (217.98) | (66.74) | (24.66) | (55.21) | (41.01) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025
Charts ten years each
Adagene Inc. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics, Inc. | $173.3M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| DTIL Precision BioSciences, Inc. | $170.3M | — (loss-making) | — (loss-making) | +37,272.41% (above 0%: growing) | n/m | +33.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CHRS Coherus Oncology, Inc. | $165.3M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $165.3M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VRXA Veraxa Biotech AG | $162.5M | — | — | — | — | — | — | — | Compare |
| CMPX Compass Therapeutics, Inc. | $161.5M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ADAG Adagene Inc. Sponsored ADR | $161.1M | — (loss-making) | — (loss-making) | — | — | −11.08% (below 0%: shrinking) | — | — | |
| MDWD MediWound Ltd. | $157.6M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| NBP NovaBridge Biosciences | $149.6M | — (loss-making) | — (loss-making) | −88.54% (below 0%: shrinking) | n/m | +34.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $163.9M | — | — | +36.51% | — | −26.05% | 89.36% | 0.00% |
Adagene Inc. Sponsored ADR (ADAG) key facts
- Strength: Adagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024.
- Adagene Inc. Sponsored ADR (ADAG) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, ADAG traded at $2.06, a market capitalization of $161.1 million.
- Return on equity was −41.0% and debt-to-equity 0.01.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −4.64 (distress zone) for fiscal 2025.
Adagene Inc. Sponsored ADR (ADAG) Latest News
No news at this impact. Lower the threshold for more.